Jain PharmaBiotech
Jain PharmaBiotech was formed by Prof. Dr. K. K. Jain in 1996 for basic as well as clinical research and to provide consulting services for the biopharmaceutical industries. Their key expertise lie in neurology, cancer, personalized medicine, cell therapy, gene therapy, RNA interference, Proteomics, Molecular diagnostics, biomarkers, nanobiotechnology, drug delivery technologies. Jain PharmaBiotech also carries lecturing activities.
Your filters
clear all
None selected
previous
| Animal Biotechnology -Technologies, Markets and Companies (JAI00024) This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the... | May 2013 | £1,925€2,280$3,000 |
| Cytogenetics -Technologies, Markets and Companies (JAI00029) This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of... | May 2013 | £1,605€1,901$2,500 |
| DNA sequencing -Technologies, Markets and Companies (JAI00042) This report briefly reviews basics of human genome variations, development of sequencing technologies, and their applications. Current large and small sequencers are described as well as companies developing them. Various... | May 2013 | £1,925€2,280$3,000 |
| Alzheimer's disease -Technologies, Markets and Companies (JAI00023) Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable... | May 2013 | £2,250€2,665$3,500 |
| Neuroprotection - Technologies, Markets and Companies (JAI00035) This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because... | May 2013 | £3,210€3,802$5,000 |
| Nitric Oxide - Therapeutics, Markets and Companies (JAI00036) This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of... | May 2013 | £1,925€2,280$3,000 |
| Biomarkers - technologies,markets and companies (JAI00026) This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well... | May 2013 | £3,210€3,802$5,000 |
| Antiviral Therapeutics -Technologies, Markets and Companies (JAI00025) This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The introduction starts with a practical classification of viral diseases according... | May 2013 | £2,250€2,665$3,500 |
| Personalized Medicine - scientific & commercial aspects (JAI00038) The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a... | May 2013 | £3,210€3,802$5,000 |
| Biochips/Microarrays -Technologies, Markets and Companies (JAI00043) This report is an analysis of biochip/microarray markets based on technologies and applications. The report starts with a description of technologies as a basis for estimation of markets. Technologies include... | May 2013 | £1,605€1,901$2,500 |
| Cardiovascular Drug Delivery -Technologies, Markets and Companies (JAI00027) Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all... | May 2013 | £1,800€2,132$2,800 |
| Drug Delivery in Cancer - technologies, markets and companies (JAI00030) Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug... | May 2013 | £2,570€3,044$4,000 |
| Cell Therapy: Technologies, Markets and Companies (JAI00047) This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing... | May 2013 | £3,535€4,187$5,500 |
| RNAi - technologies, markets and companies (JAI00040) RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material is processed into short 21-23 nucleotide RNAs termed siRNAs that... | May 2013 | £2,570€3,044$4,000 |
| Molecular Diagnostics -Technologies, Markets and Companies (JAI00051) Benefits of this report This report has evolved during the past 17 years, profiting from feedback by numerous readers and experts. The most comprehensive and up-to-date one-stop source of information on technical... | May 2013 | £3,535€4,187$5,500 |
| Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies (JAI00031) The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g.,... | May 2013 | £1,925€2,280$3,000 |
| Gene Therapy -Technologies, Markets and Companies (JAI00032) Benefits of this report Up-to-date on-stop information on gene therapy with 72 tables and 15 figures Evaluation of gene therapy technologies 740 selected references from the literature Estimates of gene therapy markets from 2012-2022 Profiles... | May 2013 | £3,210€3,802$5,000 |
| Pain Therapeutics - Drugs, Markets and Companies (JAI00037) This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis,... | May 2013 | £2,570€3,044$4,000 |
| Proteomics - Technologies, Markets and Companies (JAI00039) This report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era - the first... | May 2013 | £3,210€3,802$5,000 |
| Therapeutic Drug Monitoring - Technologies, Markets, and Companies (JAI00048) Benefits of this report Up-to-date one-stop information on therapeutic drug monitoring Description of 27 companies involved with their collaborations in this area Market analysis 2012-2022/ Market values in major regions Strategies for developing markets for... | May 2013 | £1,605€1,901$2,500 |
| Nanobiotechnology - Applications, Markets and Companies (JAI00034) Nanotechnology is the creation and utilization of materials, devices, and systems through the control of matter on the nanometer-length scale (a nanometer is one billionth of a meter. Nanobiotechnology, an... | May 2013 | £3,210€3,802$5,000 |
| Transdermal Drug Delivery - Technologies, Markets, and Companies (JAI00041) Benefits of this report Up-to-date one-stop information on transdermal drug delivery Description of 120 companies involved and 114 collaborations in this area Market analysis 2012-2022/ Market values in major regions Strategies for developing markets for... | May 2013 | £1,925€2,280$3,000 |
